Seeking spark- ocular myasthenia gravis in a juvenile – an Indian case report
Abstract
Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junction by muscle weakness. Myasthenia gravis can be generalized or localized as ocular myasthenia gravis. Case presentation: We report an 8-year-old boy who presented with 10 days history of drooping of both eyelids and 8 days history of diplopia. Examination revealed bilateral ptosis. A diagnosis of Juvenile Ocular Myasthenia gravis was made when symptoms improved with intramuscular Edrophonium administration. He was commenced on oral Neostigmine at a dose of 2mg/Kg/ day,4 hourly in divided doses and is on regular follow up and had a good response. Conclusion: Ocular Myasthenia gravis (OMG) is a rare disease in itself. A high index of suspicion is required in a juvenile as it is even rarer.
Downloads
References
Nair AG, Chhablani PP, Venkataramani DV, Gandhi RA. Ocular myasthenia gravis: A review. IJO 2014;62(10):985-991. doi: 10.4103/0301-4738.145987.
Lin CW, Chen T,Jou J, Woung L. Update on ocular myasthenia gravis in Taiwan. TJO. 2018;8(2):67-73. doi: 10.4103/tjo.tjo_39_17.
Cao Y, Bu B.Childhood-Onset Myasthenia Gravis, a Troublesome Clinical Entity with Heterogeneity in China. Arch Neurol Neurosci. 2019;2(3). doi: 10.33552/ANN.2019.02.000539.
Liew WKM, Kang PB. Update on juvenile myasthenia gravis. Curr Opin Pediatr. 2013;25(6):694-700. doi: 10.1097/MOP.0b013e328365ad16.
Solano A, Jimeno V, Montoya L, Espinosa N. Pediatric ocular myasthenia gravis: Case report and literature review. Pan Am J Ophthalmol. 2019;1(1):16. doi: 10.4103/PAJO.PAJO_11_19.
Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;150(4):453-459. doi: 10.1016/j.ajo.2010.05.002.
Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol. 2013;48(2):95-104. doi: 10.1016/j.pediatrneurol.2012.07.008.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1.
Cornblath, Wayne T. Treatment of Ocular Myasthenia Gravis. APJO. 2018;7(4):257-259. doi: 10.22608/APO.2018301.
Kusner LL, Puwanant A, Kaminski HJ. Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurol. 2006;12(5):231-239. doi: 10.1097/01.nrl.0000240856.03505.b5.
Copyright (c) 2020 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
Therapoid
